Mirum(MIRM) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million • FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March • Volixibat VISTAS and VANTAGE interim analyses scheduled for June of 2024 • Cash balance of $302.8 million as of March 31, 2024 • Conference call to provide business updates today, May 8 at 1:30 p.m. ...